Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Business Insider7d
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the ...
Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122
Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
Nasdaq5d
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
A month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have lost about 21.2% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Enid News & Eagle7d
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor,
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the ...
manilatimes7d
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the ...
Zacks.com on MSN5d
Denali Starts Dosing in Phase II Parkinson's Disease Study
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.